Dry Eye Drugs (USA)

This is a list of FDA-approved drugs for dry eye disease and certain related indications.
Please contact us with corrections or additions.

See Pipeline for drugs in the approval or drug development process.

USA

(Links click through to approval documentation)

XDEMVY (2023) [Note: We are waiting on FDA labeling document to include here]
Lotilaner 0.25%
Tarsus Pharmaceuticals
Indicated for treatment of Demodex blepharitis

VEVYE (2023)
Cyclosporine ophthalmic solution 0.1%
Novaliq
Indicated for treatment of the signs and symptoms of dry eye disease.

MIEBO (2023)
Perfluorohexyloctane ophthalmic solution
Bausch & Lomb / Novaliq
Indicated for treatment of the signs and symptoms of dry eye disease.

TYRVAYA (2021)
Varenicline solution - nasal spray 0.03mg
Oyster Point Pharma
Indicated for treatment of the signs and symptoms of dry eye disease.

EYESUVIS (2020)
Loteprednol etabonate ophthalmic suspension 0.25%
Kala Pharmaceutical
Indicated for short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

CEQUA (2018)
Cyclosporine ophthalmic solution 0.09%
Sun Pharmaceuticals.
Indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

OXERVATE (2018)
Cenegermin, a/k/a recombinant human nerve growth factor
Dompe.
Orphan drug designation for neurotrophic keratitis.

XIIDRA (2016)
Lifitegrast 5%
Shire
Indicated for treatment of signs and symptoms of dry eye disease.

RESTASIS (2003)
Cyclosporine ophthalmioc emulsion 0.05%
Allergan
Indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with KCS.

Europe

NOTE: This list has not been updated recently. Please contact us with corrections or additions.

NOVATEARS
Novaliq
Lipid layer stabilizer

OXERVATE (2018) (cenegermin, a/k/a recombinant human nerve growth factor)
Dompe.
Indicated for moderate or severe neurotrophic keratitis.

CACICOL
Corneal matrix repair therapy
Laboratoires Thea
”Intended for management of chronic corneal wound healing, such as PED and persistent corneal dystrophies with associated pain.”

VISOMITIN (Russia)
For moderate to severe dry eye
Mitotech

IKERVIS
Santen’s cyclosporine drug, approved for severe keratitis in dry eye patients for whom artificial tears aren’t enough.

Asia/AU/NZ

NOTE: This list has not been updated recently. Please contact us with corrections or additions.

DIQUAS (Japan)
Diquafosol sodium 3%
Santen

MUCOSTA (Japan)
Rebamipide ophthalmic suspension 2%
Otsuka Pharmaceutical

NOVATEARS (AU, NZ)
Novaliq
Lipid layer stabilizer